Answer for these questions in short

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have sufficient information to provide comprehensive answers to all 5 questions. Here are the answers:

Case Summary

Patient: Mr. T, 60-year-old male, 60 kg Presentation: Reduced urine output (300 mL/24h), generalized weakness, bilateral pedal edema, severe watery diarrhea (8-10 episodes/day x 4 days), poor oral intake, dizziness PMH: HTN x 10 years, Type-2 DM x 9 years, Osteoarthritis knee x 5 years Medications: Telmisartan 40mg OD, Metformin 500mg BD, Glimepiride 4mg OD, OTC Diclofenac (intermittently for knee pain) Labs: SCr 3 mg/dL, BUN 60 mg/dL, K+ 5.3 mEq/L, Na+ 132 mEq/L, FBG 146 mg/dL, Hb 12.4 g/dL; BP 90/60 mmHg, HR 103, no significant proteinuria/hematuria

Q1. Analyze Clinical History, Medications & Labs to Identify Etiology and Type of AKI

Type: Prerenal AKI (most likely), with possible superimposed intrinsic (early ATN) component.

Evidence for Prerenal:

BUN:Creatinine ratio = 60:3 = 20:1 - classic prerenal marker (Goldman-Cecil Medicine)
Oliguria (300 mL/24h) with dehydration signs (dry mucosa, hypotension, tachycardia)
Clear precipitating cause: 4 days of profuse diarrhea with poor oral intake = true intravascular volume depletion
No significant proteinuria or hematuria (rules out intrinsic glomerular disease)
No prior CKD history

KDIGO AKI Staging: SCr 3 mg/dL - assuming baseline ~0.9-1.0 mg/dL, this is a >3x rise = KDIGO Stage 3 AKI

Precipitating/Compounding Factors:

Severe diarrhea - primary driver (volume depletion)
Telmisartan (ARB) - efferent arteriolar dilation, reduces GFR when renal perfusion is already compromised
Diclofenac (NSAID) - inhibits prostaglandin-mediated afferent arteriolar dilation, further reduces renal blood flow
Triple whammy effect: Volume depletion + ARB + NSAID = catastrophic drop in GFR

Q2. How Diarrhea, Telmisartan, and Diclofenac Contributed to AKI

Individually:

Factor	Mechanism
Severe diarrhea	Direct fluid and electrolyte loss → reduced effective circulating volume → reduced renal perfusion pressure
Telmisartan (ARB)	Blocks angiotensin II at AT1 receptors → dilates efferent arteriole → drops intraglomerular pressure → in normal states protective, but when volume depleted, GFR falls precipitously
Diclofenac (NSAID)	Inhibits COX → reduced prostaglandins (PGE2, PGI2) → afferent arteriolar vasoconstriction → further decreased renal blood flow (kidneys depend on PG vasodilation when perfusion is low)

Collectively - "Triple Whammy" AKI:

The kidney compensates for low perfusion via two mechanisms: (1) afferent dilation via prostaglandins (blocked by NSAID), and (2) efferent constriction via angiotensin II (blocked by ARB)
When both compensatory mechanisms are abolished in the context of true volume depletion from diarrhea, GFR collapses. This triple combination is a well-recognized iatrogenic cause of AKI. (Goldman-Cecil Medicine, Ch. 106)

Q3. Comprehensive Pharmacotherapeutic Management Plan

Immediate (Day 1-2):

Action	Rationale
STOP Telmisartan	ARBs worsen renal perfusion in hypovolemic AKI
STOP Diclofenac	NSAIDs reduce prostaglandin-mediated renal vasodilation
STOP Metformin	Risk of lactic acidosis in renal failure (contraindicated when SCr >1.5 mg/dL in males)
STOP Glimepiride	Sulfonylurea active metabolites accumulate in renal failure → hypoglycemia risk
IV Normal Saline (0.9% NaCl)	Aggressive volume resuscitation for prerenal AKI; target UO >0.5 mL/kg/hr
Monitor K+ closely	K+ 5.3 (mild hyperkalemia); avoid K+-sparing foods/fluids; consider kayexalate if rising
Glucose monitoring	FBG 146 with no antidiabetics; sliding scale insulin if needed
Antiemetic/oral rehydration	Address diarrhea - consider oral rehydration salts or IV fluids

Ongoing:

Once SCr begins to fall and patient is euvolemic, may restart antihypertensives cautiously (prefer amlodipine CCB acutely - renally safe)
Control pain with acetaminophen (avoid NSAIDs)
If K+ >6.0 or worsening acidosis, prepare for renal replacement therapy (RRT)

Q4. Rationale for Withholding Medications and When to Safely Reintroduce

Telmisartan (ARB):

Hold because: Blocks angiotensin II-mediated efferent vasoconstriction, worsening GFR in a hypoperfused state; also causes hyperkalemia (K+ already 5.3)
Restart when: SCr returns to baseline, patient is euvolemic, K+ <5.0, typically 2-4 weeks post-recovery. ARBs are ultimately beneficial long-term for diabetic nephropathy.

Metformin:

Hold because: Renally cleared; accumulates causing lactic acidosis when eGFR <30 (this patient has acute severe renal failure)
Restart when: SCr returns to baseline and eGFR is stable >45 mL/min/1.73m², typically after 48-72 hours of confirmed renal recovery

Glimepiride (Sulfonylurea):

Hold because: Active metabolites (M1, M2) are renally excreted; accumulate in AKI causing prolonged hypoglycemia
Restart when: Renal function fully recovered; use insulin in the interim for glucose control

Diclofenac (NSAID):

Permanently avoid or use at absolute minimum given his CKD risk, diabetes, and age. Switch to acetaminophen for knee pain indefinitely.

Q5. Detailed Monitoring Plan

Clinical Parameters (Every 4-8 hours):

Blood pressure, heart rate, respiratory rate
Urine output (hourly via catheter) - target >0.5 mL/kg/hr (>30 mL/hr)
Fluid balance (input/output chart)
Signs of fluid overload (new pulmonary crackles, worsening edema, rising JVP)
Signs of dehydration (mucous membranes, skin turgor)
Level of consciousness (uremic encephalopathy)

Laboratory Investigations:

Test	Frequency	Target/Alert
Serum creatinine + BUN	Every 24 hours	Falling trend indicates recovery
Serum K+	Every 8-12 hours	Keep <5.5; >6.0 = emergency
Serum Na+	Daily	Correct hyponatremia gradually
Blood glucose	Every 6 hours	Maintain 140-180 mg/dL in hospital
Serum bicarbonate/ABG	Daily or if deteriorating	pH <7.2 = severe acidosis, consider RRT
CBC	Every 48 hours	Monitor Hb (baseline 12.4)
Urine output + spot urine Na+	Daily	FENa <1% = still prerenal

Urine Output Assessment:

Oliguria (<0.5 mL/kg/hr) - intensify IV fluids
Anuria - consider RRT if unresponsive to fluids
Increasing UO (>1 mL/kg/hr) = recovery sign

Criteria Indicating Recovery:

SCr trending down toward baseline (~1.0 mg/dL)
UO >30 mL/hr sustained
Resolving edema
Improving BUN
K+ normalizing
Patient tolerating oral fluids

Criteria Indicating Progression/Need for RRT (AEIOU indications):

Acidosis - pH <7.1 despite bicarbonate
Electrolyte imbalance - K+ >6.5 refractory to treatment
Ingestion of nephrotoxin (not applicable here)
Overload - volume overload causing pulmonary edema
Uremia - uremic encephalopathy, pericarditis, bleeding (BUN typically >100 mg/dL)

Sources: Goldman-Cecil Medicine (Acute Kidney Injury, Ch. 106); Frameworks for Internal Medicine (Prerenal AKI); Harrison's Principles of Internal Medicine 22E (AKI management); National Kidney Foundation Primer on Kidney Diseases 8e (NSAID nephrotoxicity)

Make simple and short

AKI Case - Short Answers

Patient: 60M, diarrhea x4 days, BP 90/60, UO 300mL/day, SCr 3, BUN 60, K+ 5.3, on Telmisartan + Metformin + Glimepiride + Diclofenac (OTC)

Q1. Etiology & Type of AKI

Prerenal AKI (KDIGO Stage 3)

Cause: Severe diarrhea → volume depletion → reduced renal perfusion
BUN:Cr ratio = 20:1 (classic prerenal)
Worsened by: Telmisartan (ARB) + Diclofenac (NSAID) = "Triple Whammy"
No proteinuria/hematuria = rules out intrinsic renal disease

Q2. How Each Drug + Diarrhea Contributed

Factor	Mechanism
Diarrhea	Volume loss → low renal perfusion
Telmisartan (ARB)	Blocks efferent vasoconstriction → drops GFR
Diclofenac (NSAID)	Blocks prostaglandins → afferent vasoconstriction → less blood into kidney
Together	All 3 simultaneously = GFR collapses

Q3. Management Plan

Stop nephrotoxic drugs immediately, then:

IV Normal Saline - rehydrate aggressively
Monitor urine output hourly (target >30 mL/hr)
Manage K+ (5.3 - watch closely)
Blood glucose monitoring + sliding scale insulin (held oral drugs)
Treat diarrhea - ORS or IV fluids
Analgesia - switch to Paracetamol for knee pain

Q4. Why Hold Medications & When to Restart

Drug	Why Hold	Restart When
Telmisartan	Drops GFR, worsens AKI, raises K+	SCr back to baseline + K+ <5.0 (2-4 weeks)
Metformin	Causes lactic acidosis in renal failure	eGFR >45 and stable (48-72h after recovery)
Glimepiride	Metabolites accumulate → hypoglycemia	Full renal recovery
Diclofenac	Reduces renal blood flow	Avoid permanently; use Paracetamol instead

Q5. Monitoring Plan

Clinical (every 4-8h):

BP, HR, urine output, fluid balance, edema, JVP

Labs:

Test	Frequency	Alert
SCr + BUN	Daily	Rising = worsening
K+	Every 8-12h	>6.0 = emergency
Blood glucose	Every 6h	Maintain 140-180
Bicarbonate	Daily	pH <7.2 = consider dialysis

Recovery signs: UO >30 mL/hr, SCr falling, K+ normalizing

Dialysis needed if: Refractory K+ >6.5, pH <7.1, pulmonary edema, uremic symptoms

This is a shared conversation. Sign in to Orris to start your own chat.